Chris Seagle

Chris Seagle has extensive experience in market access and pricing in the pharmaceutical and biotechnology industry. Chris is currently serving as the Vice President of Portfolio Strategy at Coherus BioSciences, a position they have held since August 2021. Prior to this role, Chris held various positions at AbbVie, including Director of Global Market Access for Oncology and Hematology Pipeline, Director of Global Strategic Pricing and Analytics, and Director of Global Market Access for Solid Tumor Oncology Portfolio. Chris also worked as a Senior Director of Oncology Global Market Access and Pricing at EMD Serono, Inc., and as a Senior Manager of Global Market Access - Oncology at sanofi-aventis. Before joining these companies, Chris worked as a Senior Consultant at Bridgehead International Ltd, where they provided pricing, reimbursement, and market access support to clients in the pharmaceutical and biotechnology sector. Chris also worked as an Independent Market Access Consultant, offering services such as revenue projections and pricing/reimbursement strategies to pharmaceutical and medical device companies. Chris began their career as a Research Assistant at the University of North Carolina at Chapel Hill.

Chris Seagle has a Ph.D. in Biomedical Engineering from the University of North Carolina at Chapel Hill. Chris also holds an MBA from UNC Kenan-Flagler Business School. In addition, they have an MS in Biomedical Engineering and a B.S. in Chemistry, both from the University of North Carolina at Chapel Hill. Furthermore, they completed an Executive Education program in Negotiation Dynamics at INSEAD, specializing in International Business.